{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T23:16:03Z","timestamp":1787786163130,"version":"build-2784847793"},"reference-count":90,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2020,4,16]],"date-time":"2020-04-16T00:00:00Z","timestamp":1586995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,4,16]],"date-time":"2020-04-16T00:00:00Z","timestamp":1586995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100008769","name":"Julius-Maximilians-Universit\u00e4t W\u00fcrzburg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100008769","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Lenalidomide is an integral, yet evolving, part of current treatment pathways for both transplant-eligible and transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM). It is approved in combination with dexamethasone as first-line therapy for transplant-ineligible patients with NDMM, and as maintenance treatment following autologous stem cell transplantation (ASCT). Although strong clinical trial evidence has supported the integration of lenalidomide into current treatment paradigms for NDMM, applying those paradigms to individual patients and determining which patients are most likely to benefit from lenalidomide treatment are more complex. In this paper, we utilize the available clinical trial evidence to provide recommendations for patient selection and lenalidomide dosing in both the first-line setting in patients ineligible for ASCT and the maintenance setting in patients who have undergone ASCT. In addition, we provide guidance on management of those adverse events that are most commonly associated with lenalidomide treatment, and consider the optimal selection and sequencing of next-line agents following long-term frontline or maintenance treatment with lenalidomide.<\/jats:p>","DOI":"10.1007\/s00277-020-04023-4","type":"journal-article","created":{"date-parts":[[2020,4,16]],"date-time":"2020-04-16T02:02:41Z","timestamp":1587002561000},"page":"1709-1725","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["The clinical management of lenalidomide-based therapy in patients with newly diagnosed multiple myeloma"],"prefix":"10.1007","volume":"99","author":[{"given":"Maximilian","family":"Merz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Dechow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mithun","family":"Scheytt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bjoern","family":"Hackanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Knop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,16]]},"reference":[{"issue":"5","key":"4023_CR1","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1046\/j.1365-2141.1998.00930.x","volume":"102","author":"J Blade","year":"1998","unstructured":"Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G, Gertz M, Giralt S, Jagannath S, Vesole D (1998) Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 102(5):1115\u20131123","journal-title":"Br J Haematol"},{"issue":"12","key":"4023_CR2","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, Kumar S, Hillengass J, Kastritis E, Richardson P, Landgren O, Paiva B, Dispenzieri A, Weiss B, LeLeu X, Zweegman S, Lonial S, Rosinol L, Zamagni E, Jagannath S, Sezer O, Kristinsson SY, Caers J, Usmani SZ, Lahuerta JJ, Johnsen HE, Beksac M, Cavo M, Goldschmidt H, Terpos E, Kyle RA, Anderson KC, Durie BG, Miguel JF (2014) International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15(12):e538\u2013e548","journal-title":"Lancet Oncol"},{"issue":"2","key":"4023_CR3","doi-asserted-by":"crossref","first-page":"197","DOI":"10.3324\/haematol.2017.174573","volume":"103","author":"F Gay","year":"2018","unstructured":"Gay F, Engelhardt M, Terpos E, Wasch R, Giaccone L, Auner HW, Caers J, Gramatzki M, van de Donk N, Oliva S, Zamagni E, Garderet L, Straka C, Hajek R, Ludwig H, Einsele H, Dimopoulos M, Boccadoro M, Kroger N, Cavo M, Goldschmidt H, Bruno B, Sonneveld P (2018) From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives. Haematologica 103(2):197\u2013211","journal-title":"Haematologica"},{"key":"4023_CR4","doi-asserted-by":"crossref","unstructured":"Rajkumar SV (2018) Multiple myeloma: 2018 update on diagnosis, risk-stratification, and management. 93(8):1091\u20131110","DOI":"10.1002\/ajh.25117"},{"issue":"9983","key":"4023_CR5","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/S0140-6736(14)60493-1","volume":"385","author":"C Rollig","year":"2015","unstructured":"Rollig C, Knop S, Bornhauser M (2015) Multiple myeloma. Lancet 385(9983):2197\u20132208","journal-title":"Lancet"},{"issue":"1","key":"4023_CR6","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1093\/jnci\/djy102","volume":"111","author":"JP Chute","year":"2019","unstructured":"Chute JP (2019) Autologous stem cell transplantation for multiple myeloma: underutilized but highly effective. J Natl Cancer Inst 111(1):7\u20138","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"4023_CR7","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1182\/blood-2017-05-693606","volume":"132","author":"S Gandolfi","year":"2018","unstructured":"Gandolfi S, Prada CP, Richardson PG (2018) How I treat the young patient with multiple myeloma. Blood 132(11):1114\u20131124","journal-title":"Blood"},{"issue":"22","key":"4023_CR8","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1182\/blood.V128.22.673.673","volume":"128","author":"M Cavo","year":"2016","unstructured":"Cavo M, Beksac M, Dimopoulos MA, Pantani L, Gay F, H\u00e1jek R, Testoni N, Mellqvist U-H, Patriarca F, Montefusco V, Galli M, Johnsen HE, Ludwig H, Zweegman S, Wester R, Wu KL, Driessen C, Troia R, Cornelisse P, van der Holt B, Palumbo A, Sonneveld P (2016) Intensification therapy with bortezomib-melphalan-prednisone versus autologous stem cell transplantation for newly diagnosed multiple myeloma: an intergroup, multicenter, phase III study of the European Myeloma Network (EMN02\/HO95 MM Trial). Blood 128(22):673\u2013673","journal-title":"Blood"},{"issue":"16","key":"4023_CR9","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/S1470-2045(15)00389-7","volume":"16","author":"F Gay","year":"2015","unstructured":"Gay F, Oliva S, Petrucci MT, Conticello C, Catalano L, Corradini P, Siniscalchi A, Magarotto V, Pour L, Carella A, Malfitano A, Petro D, Evangelista A, Spada S, Pescosta N, Omede P, Campbell P, Liberati AM, Offidani M, Ria R, Pulini S, Patriarca F, Hajek R, Spencer A, Boccadoro M, Palumbo A (2015) Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. Lancet Oncol 16(16):1617\u20131629","journal-title":"Lancet Oncol"},{"issue":"10","key":"4023_CR10","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMoa1402888","volume":"371","author":"A Palumbo","year":"2014","unstructured":"Palumbo A, Cavallo F, Gay F, Di Raimondo F, Ben Yehuda D, Petrucci MT, Pezzatti S, Caravita T, Cerrato C, Ribakovsky E, Genuardi M, Cafro A, Marcatti M, Catalano L, Offidani M, Carella AM, Zamagni E, Patriarca F, Musto P, Evangelista A, Ciccone G, Omede P, Crippa C, Corradini P, Nagler A, Boccadoro M, Cavo M (2014) Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med 371(10):895\u2013905","journal-title":"N Engl J Med"},{"issue":"8","key":"4023_CR11","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, Munshi N, Lonial S, Blade J, Mateos MV, Dimopoulos M, Kastritis E, Boccadoro M, Orlowski R, Goldschmidt H, Spencer A, Hou J, Chng WJ, Usmani SZ, Zamagni E, Shimizu K, Jagannath S, Johnsen HE, Terpos E, Reiman A, Kyle RA, Sonneveld P, Richardson PG, McCarthy P, Ludwig H, Chen W, Cavo M, Harousseau JL, Lentzsch S, Hillengass J, Palumbo A, Orfao A, Rajkumar SV, Miguel JS, Avet-Loiseau H (2016) International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 17(8):e328\u2013e346","journal-title":"Lancet Oncol"},{"issue":"2","key":"4023_CR12","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/bjh.14213","volume":"175","author":"K Yong","year":"2016","unstructured":"Yong K, Delforge M, Driessen C, Fink L, Flinois A, Gonzalez-McQuire S, Safaei R, Karlin L, Mateos MV, Raab MS, Schoen P, Cavo M (2016) Multiple myeloma: patient outcomes in real-world practice. Br J Haematol 175(2):252\u2013264","journal-title":"Br J Haematol"},{"issue":"14","key":"4023_CR13","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","volume":"376","author":"M Attal","year":"2017","unstructured":"Attal M, Lauwers-Cances V, Hulin C, Leleu X, Caillot D, Escoffre M, Arnulf B, Macro M, Belhadj K, Garderet L, Roussel M, Payen C, Mathiot C, Fermand JP, Meuleman N, Rollet S, Maglio ME, Zeytoonjian AA, Weller EA, Munshi N, Anderson KC, Richardson PG, Facon T, Avet-Loiseau H, Harousseau JL, Moreau P, for the IFM 2009 Study (2017) Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med 376(14):1311\u20131320","journal-title":"N Engl J Med"},{"key":"4023_CR14","doi-asserted-by":"crossref","unstructured":"Gay F, Cerrato C, Petrucci MT, Zambello R, Gamberi B, Ballanti S, Omed\u00e8 P, Palmieri S, Troia R, Spada S, Gozzetti A, Caravita T, Spadano A, Palumbo A, Montefusco V, Musto P, Cavo M, Boccadoro M (2019) Efficacy of carfilzomib lenalidomide dexamethasone (KRd) with or without transplantation in newly diagnosed myeloma according to risk status: results from the FORTE trial. 37(15_suppl):8002","DOI":"10.1200\/JCO.2019.37.15_suppl.8002"},{"key":"4023_CR15","unstructured":"National Comprehensive Cancer Network NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Multiple Myeloma. Version 2.2020\u2014October 19, 2019. https:\/\/www.nccn.org\/professionals\/physician_gls\/PDF\/myeloma.pdf. Accessed 18 Feb 2020"},{"issue":"10068","key":"4023_CR16","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","volume":"389","author":"BG Durie","year":"2017","unstructured":"Durie BG, Hoering A, Abidi MH, Rajkumar SV, Epstein J, Kahanic SP, Thakuri M, Reu F, Reynolds CM, Sexton R, Orlowski RZ, Barlogie B, Dispenzieri A (2017) Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet 389(10068):519\u2013527","journal-title":"Lancet"},{"issue":"6","key":"4023_CR17","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/s41375-018-0098-9","volume":"32","author":"H Avet-Loiseau","year":"2018","unstructured":"Avet-Loiseau H, Facon T (2018) Front-line therapies for elderly patients with transplant-ineligible multiple myeloma and high-risk cytogenetics in the era of novel agents. Leukemia 32(6):1267\u20131276","journal-title":"Leukemia"},{"issue":"5","key":"4023_CR18","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/CCO.0000000000000395","volume":"29","author":"S Zweegman","year":"2017","unstructured":"Zweegman S, Engelhardt M, Larocca A, EHA SWG on \u2018Aging and Hematology\u2019 (2017) Elderly patients with multiple myeloma: towards a frailty approach? Curr Opin Oncol 29(5):315\u2013321","journal-title":"Curr Opin Oncol"},{"issue":"1","key":"4023_CR19","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1053\/j.seminhematol.2018.03.001","volume":"55","author":"O Landgren","year":"2018","unstructured":"Landgren O, Lu SX, Hultcrantz M (2018) MRD testing in multiple myeloma: the main future driver for modern tailored treatment. Semin Hematol 55(1):44\u201350","journal-title":"Semin Hematol"},{"key":"4023_CR20","unstructured":"Celgene Corporation (2019) Revlimid: prescribing information. https:\/\/media.celgene.com\/content\/uploads\/revlimid-pi.pdf. Accessed 18 Feb 2020"},{"key":"4023_CR21","unstructured":"Celgene Europe Ltd (2019) Revlimid: summary of product characteristics http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000717\/WC500056018.pdf. Accessed 18 Feb 2020"},{"issue":"10","key":"4023_CR22","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa1402551","volume":"371","author":"L Benboubker","year":"2014","unstructured":"Benboubker L, Dimopoulos MA, Dispenzieri A, Catalano J, Belch AR, Cavo M, Pinto A, Weisel K, Ludwig H, Bahlis N, Banos A, Tiab M, Delforge M, Cavenagh J, Geraldes C, Lee JJ, Chen C, Oriol A, de la Rubia J, Qiu L, White DJ, Binder D, Anderson K, Fermand JP, Moreau P, Attal M, Knight R, Chen G, Van Oostendorp J, Jacques C, Ervin-Haynes A, Avet-Loiseau H, Hulin C, Facon T, for the FIRST Trial Team (2014) Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med 371(10):906\u2013917","journal-title":"N Engl J Med"},{"issue":"19","key":"4023_CR23","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1056\/NEJMoa1112704","volume":"366","author":"A Palumbo","year":"2012","unstructured":"Palumbo A, Hajek R, Delforge M, Kropff M, Petrucci MT, Catalano J, Gisslinger H, Wiktor-Jedrzejczak W, Zodelava M, Weisel K, Cascavilla N, Iosava G, Cavo M, Kloczko J, Blade J, Beksac M, Spicka I, Plesner T, Radke J, Langer C, Ben Yehuda D, Corso A, Herbein L, Yu Z, Mei J, Jacques C, Dimopoulos MA, for the MM-015 Investigators (2012) Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med 366(19):1759\u20131769","journal-title":"N Engl J Med"},{"issue":"3","key":"4023_CR24","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1182\/blood-2017-07-795047","volume":"131","author":"T Facon","year":"2018","unstructured":"Facon T, Dimopoulos MA, Dispenzieri A, Catalano JV, Belch A, Cavo M, Pinto A, Weisel K, Ludwig H, Bahlis NJ, Banos A, Tiab M, Delforge M, Cavenagh JD, Geraldes C, Lee JJ, Chen C, Oriol A, De La Rubia J, White D, Binder D, Lu J, Anderson KC, Moreau P, Attal M, Perrot A, Arnulf B, Qiu L, Roussel M, Boyle E, Manier S, Mohty M, Avet-Loiseau H, Leleu X, Ervin-Haynes A, Chen G, Houck V, Benboubker L, Hulin C (2018) Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma. Blood 131(3):301\u2013310","journal-title":"Blood"},{"key":"4023_CR25","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","volume":"380","author":"T Facon","year":"2019","unstructured":"Facon T, Kumar S, Plesner T, Orlowski RZ, Moreau P, Bahlis N, Basu S, Nahi H, Hulin C, Quach H, Goldschmidt H, O\u2019Dwyer M, Perrot A, Venner CP, Weisel K, Mace JR, Raje N, Attal M, Tiab M, Macro M, Frenzel L, Leleu X, Ahmadi T, Chiu C, Wang J, Van Rampelbergh R, Uhlar CM, Kobos R, Qi M, Usmani SZ, Trial Investigators MAIA (2019) Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. N Engl J Med 380:2104\u20132115","journal-title":"N Engl J Med"},{"issue":"9","key":"4023_CR26","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1182\/blood-2015-08-662627","volume":"127","author":"V Magarotto","year":"2016","unstructured":"Magarotto V, Bringhen S, Offidani M, Benevolo G, Patriarca F, Mina R, Falcone AP, De Paoli L, Pietrantuono G, Gentili S, Musolino C, Giuliani N, Bernardini A, Conticello C, Pulini S, Ciccone G, Maisnar V, Ruggeri M, Zambello R, Guglielmelli T, Ledda A, Liberati AM, Montefusco V, Hajek R, Boccadoro M, Palumbo A (2016) Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma. Blood 127(9):1102\u20131108","journal-title":"Blood"},{"issue":"S1","key":"4023_CR27","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/01.HS9.0000560632.24271.d7","volume":"3","author":"A Larocca","year":"2019","unstructured":"Larocca A, Salvini M, Gaidano G, Cascavilla N, Baldini L, Aglietta M, Bosi A, Marasca R, Spada S, Ledda A, Bernardini A, Falco P, De Rosa L, Guglielmelli T, Zambello R, Petrucci MT, Renzo ND, Benevolo G, Cavo M, Palumbo A, Boccadoro M, Bringhen S (2019) PF586 sparing steroids in elderly intermediate-fit newly diagnosed multiple myeloma patients treated with a dose\/schedule-adjusted Rd-R vs. continuous Rd: results of RV-MM-PI-0752 phase III randomized study. HemaSphere 3(S1):244","journal-title":"HemaSphere"},{"key":"4023_CR28","unstructured":"European Medicines Agency (2019) Darzalex summary of opinion (post authorisation). EMA\/CHMP\/530492\/2019. . https:\/\/www.ema.europa.eu\/en\/documents\/smop\/chmp-post-authorisation-summary-positive-opinion-darzalex-ii-29_en.pdf. Accessed 05 Mar 2020"},{"issue":"19","key":"4023_CR29","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","volume":"366","author":"M Attal","year":"2012","unstructured":"Attal M, Lauwers-Cances V, Marit G, Caillot D, Moreau P, Facon T, Stoppa AM, Hulin C, Benboubker L, Garderet L, Decaux O, Leyvraz S, Vekemans MC, Voillat L, Michallet M, Pegourie B, Dumontet C, Roussel M, Leleu X, Mathiot C, Payen C, Avet-Loiseau H, Harousseau JL, for the IFM Investigators (2012) Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med 366(19):1782\u20131791","journal-title":"N Engl J Med"},{"issue":"9","key":"4023_CR30","doi-asserted-by":"crossref","first-page":"e431","DOI":"10.1016\/S2352-3026(17)30140-0","volume":"4","author":"SA Holstein","year":"2017","unstructured":"Holstein SA, Jung SH, Richardson PG, Hofmeister CC, Hurd DD, Hassoun H, Giralt S, Stadtmauer EA, Weisdorf DJ, Vij R, Moreb JS, Callander NS, van Besien K, Gentile TG, Isola L, Maziarz RT, Bashey A, Landau H, Martin T, Qazilbash MH, Rodriguez C, McClune B, Schlossman RL, Smith SE, Hars V, Owzar K, Jiang C, Boyd M, Schultz C, Wilson M, Hari P, Pasquini MC, Horowitz MM, Shea TC, Devine SM, Linker C, Anderson KC, McCarthy PL (2017) Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. Lancet Haematol 4(9):e431\u2013e442","journal-title":"Lancet Haematol"},{"key":"4023_CR31","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(18)30687-9","volume":"20","author":"GH Jackson","year":"2019","unstructured":"Jackson GH, Davies FE, Pawlyn C, Cairns DA, Striha A, Collett C, Hockaday A, Jones JR, Kishore B, Garg M, Williams CD, Karunanithi K, Lindsay J, Jenner MW, Cook G, Russell NH, Kaiser MF, Drayson MT, Owen RG, Gregory WM, Morgan GJ, UK NCRI Haemato-oncology Clinical Studies Group (2019) Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 20:57\u201373","journal-title":"Lancet Oncol"},{"issue":"19","key":"4023_CR32","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMoa1114083","volume":"366","author":"PL McCarthy","year":"2012","unstructured":"McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, Richardson PG, Giralt S, Stadtmauer EA, Weisdorf DJ, Vij R, Moreb JS, Callander NS, Van Besien K, Gentile T, Isola L, Maziarz RT, Gabriel DA, Bashey A, Landau H, Martin T, Qazilbash MH, Levitan D, McClune B, Schlossman R, Hars V, Postiglione J, Jiang C, Bennett E, Barry S, Bressler L, Kelly M, Seiler M, Rosenbaum C, Hari P, Pasquini MC, Horowitz MM, Shea TC, Devine SM, Anderson KC, Linker C (2012) Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med 366(19):1770\u20131781","journal-title":"N Engl J Med"},{"issue":"29","key":"4023_CR33","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1200\/JCO.2017.72.6679","volume":"35","author":"PL McCarthy","year":"2017","unstructured":"McCarthy PL, Holstein SA, Petrucci MT, Richardson PG, Hulin C, Tosi P, Bringhen S, Musto P, Anderson KC, Caillot D, Gay F, Moreau P, Marit G, Jung SH, Yu Z, Winograd B, Knight RD, Palumbo A, Attal M (2017) Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis. J Clin Oncol 35(29):3279\u20133289","journal-title":"J Clin Oncol"},{"issue":"29","key":"4023_CR34","doi-asserted-by":"crossref","first-page":"20476","DOI":"10.18632\/oncotarget.24944","volume":"9","author":"K Fostier","year":"2018","unstructured":"Fostier K, Caers J, Meuleman N, Broos K, Corthals J, Thielemans K, Schots R, De Keersmaecker B (2018) Impact of lenalidomide maintenance on the immune environment of multiple myeloma patients with low tumor burden after autologous stem cell transplantation. Oncotarget 9(29):20476\u201320489","journal-title":"Oncotarget"},{"issue":"suppl_4","key":"4023_CR35","doi-asserted-by":"crossref","first-page":"iv52","DOI":"10.1093\/annonc\/mdx096","volume":"28","author":"P Moreau","year":"2017","unstructured":"Moreau P, San Miguel J, Sonneveld P, Mateos MV, Zamagni E, Avet-Loiseau H, Hajek R, Dimopoulos MA, Ludwig H, Einsele H, Zweegman S, Facon T, Cavo M, Terpos E, Goldschmidt H, Attal M, Buske C, on behalf of the ESMO Guidelines Committee (2017) Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 28(suppl_4):iv52\u2013iv61","journal-title":"Ann Oncol"},{"issue":"6","key":"4023_CR36","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1200\/JCO.2013.48.7934","volume":"32","author":"A Palumbo","year":"2014","unstructured":"Palumbo A, Rajkumar SV, San Miguel JF, Larocca A, Niesvizky R, Morgan G, Landgren O, Hajek R, Einsele H, Anderson KC, Dimopoulos MA, Richardson PG, Cavo M, Spencer A, Stewart AK, Shimizu K, Lonial S, Sonneveld P, Durie BG, Moreau P, Orlowski RZ (2014) International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. J Clin Oncol 32(6):587\u2013600","journal-title":"J Clin Oncol"},{"issue":"2","key":"4023_CR37","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3324\/haematol.2013.099358","volume":"99","author":"M Engelhardt","year":"2014","unstructured":"Engelhardt M, Terpos E, Kleber M, Gay F, Wasch R, Morgan G, Cavo M, van de Donk N, Beilhack A, Bruno B, Johnsen HE, Hajek R, Driessen C, Ludwig H, Beksac M, Boccadoro M, Straka C, Brighen S, Gramatzki M, Larocca A, Lokhorst H, Magarotto V, Morabito F, Dimopoulos MA, Einsele H, Sonneveld P, Palumbo A, on behalf of the European Myeloma Network (2014) European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. Haematologica 99(2):232\u2013242","journal-title":"Haematologica"},{"issue":"3","key":"4023_CR38","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3324\/haematol.2015.133629","volume":"101","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos MA, Cheung MC, Roussel M, Liu T, Gamberi B, Kolb B, Derigs HG, Eom H, Belhadj K, Lenain P, Van der Jagt R, Rigaudeau S, Dib M, Hall R, Jardel H, Jaccard A, Tosikyan A, Karlin L, Bensinger W, Schots R, Leupin N, Chen G, Marek J, Ervin-Haynes A, Facon T (2016) Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma. Haematologica 101(3):363\u2013370","journal-title":"Haematologica"},{"issue":"13","key":"4023_CR39","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1200\/JCO.2015.65.0044","volume":"34","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos MA, Sonneveld P, Leung N, Merlini G, Ludwig H, Kastritis E, Goldschmidt H, Joshua D, Orlowski RZ, Powles R, Vesole DH, Garderet L, Einsele H, Palumbo A, Cavo M, Richardson PG, Moreau P, San Miguel J, Rajkumar SV, Durie BG, Terpos E (2016) International Myeloma Working Group recommendations for the diagnosis and management of myeloma-related renal impairment. J Clin Oncol 34(13):1544\u20131557","journal-title":"J Clin Oncol"},{"issue":"30","key":"4023_CR40","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1200\/JCO.2016.66.7295","volume":"34","author":"C Hulin","year":"2016","unstructured":"Hulin C, Belch A, Shustik C, Petrucci MT, Duhrsen U, Lu J, Song K, Rodon P, Pegourie B, Garderet L, Hunter H, Azais I, Eek R, Gisslinger H, Macro M, Dakhil S, Goncalves C, LeBlanc R, Romeril K, Royer B, Doyen C, Leleu X, Offner F, Leupin N, Houck V, Chen G, Ervin-Haynes A, Dimopoulos MA, Facon T (2016) Updated outcomes and impact of age with lenalidomide and low-dose dexamethasone or melphalan, prednisone, and thalidomide in the randomized, phase III FIRST trial. J Clin Oncol 34(30):3609\u20133617","journal-title":"J Clin Oncol"},{"key":"4023_CR41","doi-asserted-by":"publisher","unstructured":"Larocca A, Mina R, Offidani M, Liberati AM, Ledda A, Patriarca F, Evangelista A, Spada S, Benevolo G, Oddolo D, Innao V, Cangialosi C, Bernardini A, Musto P, Amico V, Fraticelli V, Paris L, Giuliani N, Falcone AP, Zambello R, De Paoli L, Romano A, Palumbo A, Montefusco V, Hajek R, Boccadoro M, Bringhen S (2019) First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials. Haematologica. https:\/\/doi.org\/10.3324\/haematol.2019.220657","DOI":"10.3324\/haematol.2019.220657"},{"issue":"24","key":"4023_CR42","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1182\/blood-2016-01-631200","volume":"127","author":"P Sonneveld","year":"2016","unstructured":"Sonneveld P, Avet-Loiseau H, Lonial S, Usmani S, Siegel D, Anderson KC, Chng WJ, Moreau P, Attal M, Kyle RA, Caers J, Hillengass J, San Miguel J, van de Donk NW, Einsele H, Blade J, Durie BG, Goldschmidt H, Mateos MV, Palumbo A, Orlowski R (2016) Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood 127(24):2955\u20132962","journal-title":"Blood"},{"key":"4023_CR43","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.2147\/DDDT.S198117","volume":"13","author":"Z Ye","year":"2019","unstructured":"Ye Z, Chen J, Xuan Z, Yang W, Chen J (2019) Subcutaneous bortezomib might be standard of care for patients with multiple myeloma: a systematic review and meta-analysis. Drug Des Devel Ther 13:1707\u20131716","journal-title":"Drug Des Devel Ther"},{"issue":"Suppl 1","key":"4023_CR44","first-page":"3132","volume":"130","author":"H Cherniawsky","year":"2017","unstructured":"Cherniawsky H, Sandhu I, Chu MP, Hewitt JD, Ismail I, Belch A, Pilarski LM, Nikitina T, Venner CP (2017) The survival impact of lenalidomide maintenance chemotherapy in multiple myeloma patients treated with autologous stem cell transplant and bortezomib-based induction: an analysis of real world data. Blood 130(Suppl 1):3132\u20133132","journal-title":"Blood"},{"issue":"Suppl 1","key":"4023_CR45","first-page":"3463","volume":"130","author":"R Fonseca","year":"2017","unstructured":"Fonseca R, Parikh K, Ung B, Ni Q, Abouzaid S, Agarwal A (2017) Real-world outcomes for maintenance treatment sequencing after receiving lenalidomide, bortezomib, and dexamethasone induction in patients with newly diagnosed multiple myeloma (NDMM) followed by autologous stem cell transplant (ASCT). Blood 130(Suppl 1):3463\u20133463","journal-title":"Blood"},{"issue":"15(suppl)","key":"4023_CR46","doi-asserted-by":"crossref","first-page":"e20041","DOI":"10.1200\/JCO.2018.36.15_suppl.e20041","volume":"36","author":"R Fonseca","year":"2018","unstructured":"Fonseca R, Parikh K, Ung B, Ni Q, Agarwal A (2018) Maintenance (MT) treatment (Tx) after lenalidomide, bortezomib, and dexamethasone (RVD) induction and stem cell transplant (SCT) in high-risk (HR) patients (pts) with newly diagnosed multiple myeloma (NDMM): a real-world analysis. J Clin Oncol 36(15(suppl)):e20041","journal-title":"J Clin Oncol"},{"issue":"2","key":"4023_CR47","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/leu.2017.211","volume":"32","author":"H Goldschmidt","year":"2018","unstructured":"Goldschmidt H, Lokhorst HM, Mai EK, van der Holt B, Blau IW, Zweegman S, Weisel KC, Vellenga E, Pfreundschuh M, Kersten MJ, Scheid C, Croockewit S, Raymakers R, Hose D, Potamianou A, Jauch A, Hillengass J, Stevens-Kroef M, Raab MS, Broijl A, Lindemann HW, Bos GMJ, Brossart P, van Marwijk KM, Ypma P, Duehrsen U, Schaafsma RM, Bertsch U, Hielscher T, Jarari L, Salwender HJ, Sonneveld P (2018) Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65\/GMMG-HD4 trial. Leukemia 32(2):383\u2013390","journal-title":"Leukemia"},{"issue":"Suppl 1","key":"4023_CR48","first-page":"3462","volume":"130","author":"C Yang","year":"2017","unstructured":"Yang C, Jiang H, Masih-Khan E, Chen CI, Prica A, Reece D, Tiedemann R, Trudel S, Kukreti V (2017) Tolerability and efficacy of post transplant lenalidomide maintenance therapy in multiple myeloma: a real world single centre experience. Blood 130(Suppl 1):3462\u20133462","journal-title":"Blood"},{"issue":"24","key":"4023_CR49","doi-asserted-by":"crossref","first-page":"3831","DOI":"10.1002\/cncr.30366","volume":"122","author":"I Mian","year":"2016","unstructured":"Mian I, Milton DR, Shah N, Nieto Y, Popat UR, Kebriaei P, Parmar S, Oran B, Shah JJ, Manasanch EE, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH, Bashir Q (2016) Prolonged survival with a longer duration of maintenance lenalidomide after autologous hematopoietic stem cell transplantation for multiple myeloma. Cancer 122(24):3831\u20133837","journal-title":"Cancer"},{"issue":"Suppl 1","key":"4023_CR50","first-page":"400","volume":"130","author":"H Goldschmidt","year":"2017","unstructured":"Goldschmidt H, Mai EK, D\u00fcrig J, Scheid C, Weisel KC, Kunz C, Bertsch U, Hielscher T, Munder M, Lindemann H-W, Huegle-Doerr B, Hose D, Seckinger A, Huhn S, Jauch A, Rabold B, Elmaagacli A, Gerecke C, Brossart P, Goerner M, Bernhard H, Hoffmann M, Hillengass J, Raab M-SS, Blau IW, H\u00e4nel M, Salwender HJ (2017) Response-adapted lenalidomide maintenance in newly diagnosed, transplant-eligible multiple myeloma: results from the multicenter phase III GMMG-MM5 trial. Blood 130(Suppl 1):400\u2013400","journal-title":"Blood"},{"issue":"1","key":"4023_CR51","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1517\/14740338.2011.619975","volume":"11","author":"A Palumbo","year":"2012","unstructured":"Palumbo A, Freeman J, Weiss L, Fenaux P (2012) The clinical safety of lenalidomide in multiple myeloma and myelodysplastic syndromes. Expert Opin Drug Saf 11(1):107\u2013120","journal-title":"Expert Opin Drug Saf"},{"issue":"5","key":"4023_CR52","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.clml.2017.02.024","volume":"17","author":"SK Kumar","year":"2017","unstructured":"Kumar SK, Vij R, Noga SJ, Berg D, Brent L, Dollar L, Chari A (2017) Treating multiple myeloma patients with oral therapies. Clin Lymphoma Myeloma Leuk 17(5):243\u2013251","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"10","key":"4023_CR53","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.3324\/haematol.2014.117176","volume":"100","author":"E Terpos","year":"2015","unstructured":"Terpos E, Kleber M, Engelhardt M, Zweegman S, Gay F, Kastritis E, van de Donk NW, Bruno B, Sezer O, Broijl A, Bringhen S, Beksac M, Larocca A, Hajek R, Musto P, Johnsen HE, Morabito F, Ludwig H, Cavo M, Einsele H, Sonneveld P, Dimopoulos MA, Palumbo A, on behalf of the European Myeloma Network (2015) European Myeloma Network guidelines for the management of multiple myeloma-related complications. Haematologica 100(10):1254\u20131266","journal-title":"Haematologica"},{"issue":"19","key":"4023_CR54","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1056\/NEJMc053530","volume":"354","author":"R Knight","year":"2006","unstructured":"Knight R, DeLap RJ, Zeldis JB (2006) Lenalidomide and venous thrombosis in multiple myeloma. N Engl J Med 354(19):2079\u20132080","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"4023_CR55","first-page":"553","volume":"130","author":"CA Bradbury","year":"2017","unstructured":"Bradbury CA, Jenner MW, Striha A, Cook G, Pawlyn C, Jones JR, Cairns D, Hockaday A, Paterson A, Drayson MT, Owen RG, Kaiser MF, Gregory WM, Davies FE, Morgan GJ, Jackson GH (2017) Thrombotic events in patients with myeloma treated with immunomodulatory drugs: results of the Myeloma XI study. Blood 130(Suppl 1):553\u2013553","journal-title":"Blood"},{"issue":"4","key":"4023_CR56","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1182\/blood-2011-03-344333","volume":"119","author":"A Larocca","year":"2012","unstructured":"Larocca A, Cavallo F, Bringhen S, Di Raimondo F, Falanga A, Evangelista A, Cavalli M, Stanevsky A, Corradini P, Pezzatti S, Patriarca F, Cavo M, Peccatori J, Catalano L, Carella AM, Cafro AM, Siniscalchi A, Crippa C, Petrucci MT, Yehuda DB, Beggiato E, Di Toritto TC, Boccadoro M, Nagler A, Palumbo A (2012) Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. Blood 119(4):933\u2013939","journal-title":"Blood"},{"issue":"2","key":"4023_CR57","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/sj.leu.2405062","volume":"22","author":"A Palumbo","year":"2008","unstructured":"Palumbo A, Rajkumar SV, Dimopoulos MA, Richardson PG, San Miguel J, Barlogie B, Harousseau J, Zonder JA, Cavo M, Zangari M, Attal M, Belch A, Knop S, Joshua D, Sezer O, Ludwig H, Vesole D, Blade J, Kyle R, Westin J, Weber D, Bringhen S, Niesvizky R, Waage A, von Lilienfeld-Toal M, Lonial S, Morgan GJ, Orlowski RZ, Shimizu K, Anderson KC, Boccadoro M, Durie BG, Sonneveld P, Hussein MA, on behalf of the International Myeloma Working Group (2008) Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 22(2):414\u2013423","journal-title":"Leukemia"},{"key":"4023_CR58","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/bjh.15392","volume":"185","author":"NPF Storrar","year":"2018","unstructured":"Storrar NPF, Mathur A, Johnson PRE, Roddie PH (2018) Safety and efficacy of apixaban for routine thromboprophylaxis in myeloma patients treated with thalidomide- and lenalidomide-containing regimens. Br J Haematol 185:142\u2013144","journal-title":"Br J Haematol"},{"issue":"Suppl","key":"4023_CR59","doi-asserted-by":"crossref","first-page":"S64","DOI":"10.1016\/j.clml.2015.02.008","volume":"15","author":"SM Tinsley","year":"2015","unstructured":"Tinsley SM, Kurtin SE, Ridgeway JA (2015) Practical management of lenalidomide-related rash. Clin Lymphoma Myeloma Leuk 15(Suppl):S64\u2013S69","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"12","key":"4023_CR60","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1002\/ajh.23835","volume":"89","author":"P Tacchetti","year":"2014","unstructured":"Tacchetti P, Terragna C, Galli M, Zamagni E, Petrucci MT, Pezzi A, Montefusco V, Martello M, Tosi P, Baldini L, Peccatori J, Ruggieri M, Pantani L, Lazzaro A, Elice F, Rocchi S, Gozzetti A, Cavaletti G, Palumbo A, Cavo M (2014) Bortezomib- and thalidomide-induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 study. Am J Hematol 89(12):1085\u20131091","journal-title":"Am J Hematol"},{"issue":"4","key":"4023_CR61","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/leu.2011.346","volume":"26","author":"PG Richardson","year":"2012","unstructured":"Richardson PG, Delforge M, Beksac M, Wen P, Jongen JL, Sezer O, Terpos E, Munshi N, Palumbo A, Rajkumar SV, Harousseau JL, Moreau P, Avet-Loiseau H, Lee JH, Cavo M, Merlini G, Voorhees P, Chng WJ, Mazumder A, Usmani S, Einsele H, Comenzo R, Orlowski R, Vesole D, Lahuerta JJ, Niesvizky R, Siegel D, Mateos MV, Dimopoulos M, Lonial S, Jagannath S, Blade J, Miguel JS, Morgan G, Anderson KC, Durie BG, Sonneveld P (2012) Management of treatment-emergent peripheral neuropathy in multiple myeloma. Leukemia 26(4):595\u2013608","journal-title":"Leukemia"},{"issue":"12","key":"4023_CR62","doi-asserted-by":"crossref","first-page":"e485","DOI":"10.3324\/haematol.2016.151266","volume":"101","author":"M Merz","year":"2016","unstructured":"Merz M, Salwender H, Haenel M, Mai EK, Bertsch U, Kunz C, Hielscher T, Blau IW, Scheid C, Hose D, Seckinger A, Jauch A, Hillengass J, Raab MS, Schurich B, Munder M, Brossart P, Gerecke C, Lindemann HW, Zeis M, Weisel K, Duerig J, Goldschmidt H (2016) Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trial. Haematologica 101(12):e485\u2013e487","journal-title":"Haematologica"},{"issue":"1","key":"4023_CR63","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/s41375-018-0195-9","volume":"33","author":"EK Mai","year":"2019","unstructured":"Mai EK, Hielscher T, Bertsch U, Schlenzka J, Salwender HJ, Munder M, Gerecke C, Duhrsen U, Brossart P, Neben K, Hillengass J, Raab MS, Merz M, Baertsch MA, Jauch A, Hose D, Martin H, Lindemann HW, Blau IW, Scheid C, Weisel KC, Goldschmidt H, German-speaking Myeloma Multicenter G (2019) Bortezomib-based induction therapy with high or low-dose dexamethasone in newly diagnosed, transplant-eligible multiple myeloma. Leukemia 33(1):258\u2013261","journal-title":"Leukemia"},{"issue":"5","key":"4023_CR64","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/leu.2011.3","volume":"25","author":"MA Dimopoulos","year":"2011","unstructured":"Dimopoulos MA, Palumbo A, Attal M, Beksac M, Davies FE, Delforge M, Einsele H, Hajek R, Harousseau JL, da Costa FL, Ludwig H, Mellqvist UH, Morgan GJ, San-Miguel JF, Zweegman S, Sonneveld P, on behalf of the European Myeloma Network (2011) Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement. Leukemia 25(5):749\u2013760","journal-title":"Leukemia"},{"issue":"5","key":"4023_CR65","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1007\/s00520-014-2552-1","volume":"23","author":"K Colson","year":"2015","unstructured":"Colson K (2015) Treatment-related symptom management in patients with multiple myeloma: a review. Support Care Cancer 23(5):1431\u20131445","journal-title":"Support Care Cancer"},{"issue":"4","key":"4023_CR66","doi-asserted-by":"crossref","first-page":"E100","DOI":"10.1188\/16.CJON.E100-E105","volume":"20","author":"B Faiman","year":"2016","unstructured":"Faiman B (2016) Diarrhea in multiple myeloma: a review of the literature. Clin J Oncol Nurs 20(4):E100\u2013E105","journal-title":"Clin J Oncol Nurs"},{"issue":"15","key":"4023_CR67","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1182\/blood-2014-06-583302","volume":"124","author":"C Pawlyn","year":"2014","unstructured":"Pawlyn C, Khan MS, Muls A, Sriskandarajah P, Kaiser MF, Davies FE, Morgan GJ, Andreyev HJ (2014) Lenalidomide-induced diarrhea in patients with myeloma is caused by bile acid malabsorption that responds to treatment. Blood 124(15):2467\u20132468","journal-title":"Blood"},{"issue":"3 Suppl","key":"4023_CR68","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1188\/08.CJON.S1.37-51","volume":"12","author":"LC Smith","year":"2008","unstructured":"Smith LC, Bertolotti P, Curran K, Jenkins B, Nurse Leadership Board IMF (2008) Gastrointestinal side effects associated with novel therapies in patients with multiple myeloma: consensus statement of the IMF Nurse Leadership Board. Clin J Oncol Nurs 12(3 Suppl):37\u201352","journal-title":"Clin J Oncol Nurs"},{"issue":"9","key":"4023_CR69","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.4103\/0366-6999.156134","volume":"128","author":"SK Qiao","year":"2015","unstructured":"Qiao SK, Guo XN, Ren JH, Ren HY (2015) Efficacy and safety of lenalidomide in the treatment of multiple myeloma: a systematic review and meta-analysis of randomized controlled trials. Chin Med J 128(9):1215\u20131222","journal-title":"Chin Med J"},{"issue":"3","key":"4023_CR70","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/NCC.0b013e3181f9904d","volume":"34","author":"EA Coleman","year":"2011","unstructured":"Coleman EA, Goodwin JA, Coon SK, Richards K, Enderlin C, Kennedy R, Stewart CB, McNatt P, Lockhart K, Anaissie EJ, Barlogie B (2011) Fatigue, sleep, pain, mood, and performance status in patients with multiple myeloma. Cancer Nurs 34(3):219\u2013227","journal-title":"Cancer Nurs"},{"issue":"6","key":"4023_CR71","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/s41409-018-0177-6","volume":"53","author":"J Huang","year":"2018","unstructured":"Huang J, Phillips S, Byrne M, Chinratanalab W, Engelhardt BG, Goodman SA, Harrell SL, Jagasia M, Kassim A, Rawling KT, Savani BN, Sengsayadeth S, Cornell RF (2018) Lenalidomide vs bortezomib maintenance choice post-autologous hematopoietic cell transplantation for multiple myeloma. Bone Marrow Transplant 53(6):701\u2013707","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"4023_CR72","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1111\/bjh.14514","volume":"176","author":"JA Snowden","year":"2017","unstructured":"Snowden JA, Greenfield DM, Bird JM, Boland E, Bowcock S, Fisher A, Low E, Morris M, Yong K, Pratt G, on behalf of the UK Myeloma Forum (UKMF) and the British Society for Haematology (BSH) (2017) Guidelines for screening and management of late and long-term consequences of myeloma and its treatment. Br J Haematol 176(6):888\u2013907","journal-title":"Br J Haematol"},{"issue":"6","key":"4023_CR73","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s00277-018-3284-y","volume":"97","author":"M Chen","year":"2018","unstructured":"Chen M, Zhao Y, Xu C, Wang X, Zhang X, Mao B (2018) Immunomodulatory drugs and the risk of serious infection in multiple myeloma: systematic review and meta-analysis of randomized and observational studies. Ann Hematol 97(6):925\u2013944","journal-title":"Ann Hematol"},{"issue":"28","key":"4023_CR74","doi-asserted-by":"crossref","first-page":"46593","DOI":"10.18632\/oncotarget.16235","volume":"8","author":"L Ying","year":"2017","unstructured":"Ying L, YinHui T, Yunliang Z, Sun H (2017) Lenalidomide and the risk of serious infection in patients with multiple myeloma: a systematic review and meta-analysis. Oncotarget 8(28):46593\u201346600","journal-title":"Oncotarget"},{"issue":"2","key":"4023_CR75","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/cei.12343","volume":"177","author":"A Busch","year":"2014","unstructured":"Busch A, Zeh D, Janzen V, Mugge LO, Wolf D, Fingerhut L, Hahn-Ast C, Maurer O, Brossart P, von Lilienfeld-Toal M (2014) Treatment with lenalidomide induces immunoactivating and counter-regulatory immunosuppressive changes in myeloma patients. Clin Exp Immunol 177(2):439\u2013453","journal-title":"Clin Exp Immunol"},{"issue":"3","key":"4023_CR76","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00277-013-1951-6","volume":"93","author":"C Konig","year":"2014","unstructured":"Konig C, Kleber M, Reinhardt H, Knop S, Wasch R, Engelhardt M (2014) Incidence, risk factors, and implemented prophylaxis of varicella zoster virus infection, including complicated varicella zoster virus and herpes simplex virus infections, in lenalidomide-treated multiple myeloma patients. Ann Hematol 93(3):479\u2013484","journal-title":"Ann Hematol"},{"issue":"4","key":"4023_CR77","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.bbmt.2017.12.795","volume":"24","author":"M Palazzo","year":"2018","unstructured":"Palazzo M, Shah GL, Copelan O, Seier K, Devlin SM, Maloy M, Kenny S, Hassoun H, Korde NS, Lendvai N, Lesokhin AM, Mailankody S, Chung DJ, Koehne G, Landgren CO, Landau H, Giralt SA, Perales MA (2018) Revaccination after autologous hematopoietic stem cell transplantation is safe and effective in patients with multiple myeloma receiving lenalidomide maintenance. Biol Blood Marrow Transplant 24(4):871\u2013876","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"4023_CR78","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/s41409-018-0112-x","volume":"53","author":"A Pandit","year":"2018","unstructured":"Pandit A, Leblebjian H, Hammond SP, Laubach JP, Richardson PG, Baden LR, Marty FM, Issa NC (2018) Safety of live-attenuated measles-mumps-rubella and herpes zoster vaccination in multiple myeloma patients on maintenance lenalidomide or bortezomib after autologous hematopoietic cell transplantation. Bone Marrow Transplant 53(7):942\u2013945","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"4023_CR79","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S1470-2045(13)70609-0","volume":"15","author":"A Palumbo","year":"2014","unstructured":"Palumbo A, Bringhen S, Kumar SK, Lupparelli G, Usmani S, Waage A, Larocca A, van der Holt B, Musto P, Offidani M, Petrucci MT, Evangelista A, Zweegman S, Nooka AK, Spencer A, Dimopoulos MA, Hajek R, Cavo M, Richardson P, Lonial S, Ciccone G, Boccadoro M, Anderson K, Barlogie B, Sonneveld P, McCarthy PL (2014) Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. Lancet Oncol 15(3):333\u2013342","journal-title":"Lancet Oncol"},{"key":"4023_CR80","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/bjc.1987.107","volume":"55","author":"J Cuzik","year":"1987","unstructured":"Cuzik J, Erskine S, Edelman D, Galton GAG (1987) A comparison of the incidence of the myelodysplastic syndrome and acute myeloid leukaemia following melphalan and cyclophosphamide treatment for myelomatosis. Br J Cancer 55:523\u2013529","journal-title":"Br J Cancer"},{"issue":"12","key":"4023_CR81","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2016.114","volume":"6","author":"JR Jones","year":"2016","unstructured":"Jones JR, Cairns DA, Gregory WM, Collett C, Pawlyn C, Sigsworth R, Striha A, Henderson R, Kaiser MF, Jenner M, Cook G, Russell NH, Williams C, Pratt G, Kishore B, Lindsay J, Drayson MT, Davies FE, Boyd KD, Owen RG, Jackson GH, Morgan GJ (2016) Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial. Blood Cancer J 6(12):e506","journal-title":"Blood Cancer J"},{"issue":"2","key":"4023_CR82","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1093\/annonc\/mdw606","volume":"28","author":"P Musto","year":"2017","unstructured":"Musto P, Anderson KC, Attal M, Richardson PG, Badros A, Hou J, Comenzo R, Du J, Durie BGM, San Miguel J, Einsele H, Chen WM, Garderet L, Pietrantuono G, Hillengass J, Kyle RA, Moreau P, Lahuerta JJ, Landgren O, Ludwig H, Larocca A, Mahindra A, Cavo M, Mazumder A, McCarthy PL, Nouel A, Rajkumar SV, Reiman A, Riva E, Sezer O, Terpos E, Turesson I, Usmani S, Weiss BM, Palumbo A, on behalf of the International Myeloma Working Group (2017) Second primary malignancies in multiple myeloma: an overview and IMWG consensus. Ann Oncol 28(2):228\u2013245","journal-title":"Ann Oncol"},{"issue":"1","key":"4023_CR83","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1080\/10428194.2016.1177772","volume":"58","author":"K Weisel","year":"2017","unstructured":"Weisel K, Doyen C, Dimopoulos M, Yee A, Lahuerta JJ, Martin A, Travers K, Druyts E, Toor K, Abildgaard N, Lu J, Van Droogenbroeck J, Geraldes C, Petrini M, Voillat L, Voog E, Facon T (2017) A systematic literature review and network meta-analysis of treatments for patients with untreated multiple myeloma not eligible for stem cell transplantation. Leuk Lymphoma 58(1):153\u2013161","journal-title":"Leuk Lymphoma"},{"issue":"s103","key":"4023_CR84","first-page":"S185","volume":"103","author":"C Cerchione","year":"2018","unstructured":"Cerchione C, Ferrara K (2018) Carfilzomib-lenalidomide-dexamethasone in the management of lenalidomide-refractory multiple myeloma. Haematologica 103(s103):S185","journal-title":"Haematologica"},{"issue":"19","key":"4023_CR85","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1182\/blood-2016-07-729236","volume":"128","author":"IS Nijhof","year":"2016","unstructured":"Nijhof IS, Franssen LE, Levin MD, Bos GMJ, Broijl A, Klein SK, Koene HR, Bloem AC, Beeker A, Faber LM, van der Spek E, Ypma PF, Raymakers R, van Spronsen DJ, Westerweel PE, Oostvogels R, van Velzen J, van Kessel B, Mutis T, Sonneveld P, Zweegman S, Lokhorst HM, van de Donk N (2016) Phase 1\/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma. Blood 128(19):2297\u20132306","journal-title":"Blood"},{"issue":"2","key":"4023_CR86","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/j.1365-2141.2009.07931.x","volume":"148","author":"NW van de Donk","year":"2010","unstructured":"van de Donk NW, Wittebol S, Minnema MC, Lokhorst HM (2010) Lenalidomide (Revlimid) combined with continuous oral cyclophosphamide (endoxan) and prednisone (REP) is effective in lenalidomide\/dexamethasone-refractory myeloma. Br J Haematol 148(2):335\u2013337","journal-title":"Br J Haematol"},{"issue":"2","key":"4023_CR87","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1179\/0001551214Z.00000000030","volume":"69","author":"N Zelis","year":"2014","unstructured":"Zelis N, Devos T, Dierickx D, Janssens A, Raddoux J, Verhoef G, Delforge M (2014) Treatment with lenalidomide (Revlimid(R)), cyclophosphamide (Endoxan(R)) and prednisone (REP) in relapsed\/refractory multiple myeloma patients: results of a single centre retrospective study. Acta Clin Belg 69(2):98\u2013103","journal-title":"Acta Clin Belg"},{"issue":"4","key":"4023_CR88","doi-asserted-by":"crossref","first-page":"396","DOI":"10.3324\/haematol.2015.129189","volume":"101","author":"P Sonneveld","year":"2016","unstructured":"Sonneveld P, Broijl A (2016) Treatment of relapsed and refractory multiple myeloma. Haematologica 101(4):396\u2013406","journal-title":"Haematologica"},{"key":"4023_CR89","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1470-2045(19)30152-4","volume":"20","author":"PG Richardson","year":"2019","unstructured":"Richardson PG, Oriol A, Beksac M, Liberati AM, Galli M, Schjesvold F, Lindsay J, Weisel K, White D, Facon T, San Miguel J, Sunami K, O\u2019Gorman P, Sonneveld P, Robak P, Semochkin S, Schey S, Yu X, Doerr T, Bensmaine A, Biyukov T, Peluso T, Zaki M, Anderson K, Dimopoulos M, OPTIMISMM trial investigators (2019) Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. Lancet Oncol 20:781\u2013794","journal-title":"Lancet Oncol"},{"key":"4023_CR90","unstructured":"Bristol-Myers Squibb (2019) Empliciti prescribing information. http:\/\/packageinserts.bms.com\/pi\/pi_empliciti.pdf. Accessed 25 Feb 2020"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-020-04023-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-020-04023-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-020-04023-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,15]],"date-time":"2021-04-15T23:46:17Z","timestamp":1618530377000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-020-04023-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,16]]},"references-count":90,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["4023"],"URL":"https:\/\/doi.org\/10.1007\/s00277-020-04023-4","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,16]]},"assertion":[{"value":"31 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"MM has received consultancy fees from Amgen and Takeda, research support from Takeda, and travel grants from Abbvie, Amgen, Takeda, and Celgene. CS has served on advisory councils\/committees for Kite Gilead and Novartis, and received honoraria from Roche, Novartis, and Kite Gilead, and research support from Janssen. BH has served on advisory councils\/committees for Boehringer Ingelheim, Roche, BMS, Novartis, and Abbvie. SK has received consultancy fees from Bristol-Myers Squibb, Amgen, Celgene, and Oncopeptides; served on advisory councils\/committees for Bristol-Myers Squibb, Amgen, Celgene, and Oncopeptides; and received honoraria from Bristol-Myers Squibb, Amgen, Celgene, Janssen, and Oncopeptides. TD and MS declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}